Novel Cecropin-4 Derived Peptides against Methicillin-Resistant Staphylococcus aureus
Open Access
- 1 January 2021
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 10 (1) , 36
Abstract
Increasing microbial resistance, coupled with a lack of new antimicrobial discovery, has led researchers to refocus on antimicrobial peptides (AMPs) as novel therapeutic candidates. Significantly, the less toxic cecropins have gained widespread attention for potential antibacterial agent development. However, the narrow activity spectrum and long sequence remain the primary limitations of this approach. In this study, we truncated and modified cecropin 4 (41 amino acids) by varying the charge and hydrophobicity balance to obtain smaller AMPs. The derivative peptide C18 (16 amino acids) demonstrated high antibacterial activity against Gram-negative and Gram-positive bacteria, as well as yeasts. Moreover, C18 demonstrated a minimal inhibitory concentration (MIC) of 4 µg/mL against the methicillin-resistant Staphylococcus aureus (MRSA) and showed synergy with daptomycin with a fractional inhibition concentration index (FICI) value of 0.313. Similar to traditional cecropins, C18 altered the membrane potential, increased fluidity, and caused membrane breakage at 32 µg/mL. Importantly, C18 eliminated 99% persisters at 10 × MIC within 20 min and reduced the biofilm adherence by ~40% and 35% at 32 and 16 µg/mL. Besides, C18 possessed a strong binding ability with DNA at 7.8 μM and down-regulated the expression of virulence factor genes like agrA, fnb-A, and clf-1 by more than 5-fold (p < 0.05). Interestingly, in the Galleria mellonella model, C18 rescued more than 80% of larva infected with the MRSA throughout 120-h post-infection at a single dose of 8 mg/kg (p < 0.05). In conclusion, this study provides a reference for the transformation of cecropin to derive small peptides and presents C18 as an attractive therapeutic candidate to be developed to treat severe MRSA infections.Keywords
This publication has 50 references indexed in Scilit:
- PRO: The COVID-19 pandemic will result in increased antimicrobial resistance ratesJAC-Antimicrobial Resistance, 2020
- The Novel Coronavirus COVID-19 Outbreak: Global Implications for Antimicrobial ResistanceFrontiers in Microbiology, 2020
- Antimicrobial host defence peptides: functions and clinical potentialNature Reviews Drug Discovery, 2020
- Comparative efficacy and safety of vancomycin versus teicoplanin in febrile neutropenic patients receiving hematopoietic stem cell transplantationJournal of Clinical Pharmacy and Therapeutics, 2019
- Vital Signs:Epidemiology and Recent Trends in Methicillin-Resistant and in Methicillin-SusceptibleStaphylococcus aureusBloodstream Infections — United StatesMMWR. Morbidity and Mortality Weekly Report, 2019
- Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosisThe Lancet Infectious Diseases, 2018
- Host defense antimicrobial peptides as antibiotics: design and application strategiesCurrent Opinion in Chemical Biology, 2017
- Multicenter Prospective Observational Study of the Comparative Efficacy and Safety of Vancomycin versus Teicoplanin in Patients with Health Care-Associated Methicillin-Resistant Staphylococcus aureus BacteremiaAntimicrobial Agents and Chemotherapy, 2014
- The Importance of Amino Acid Composition in Natural AMPs: An Evolutional, Structural, and Functional PerspectiveFrontiers in Immunology, 2012
- High-Dose Vancomycin Therapy for Methicillin-Resistant Staphylococcus aureus InfectionsArchives of internal medicine (1960), 2006